Physician profile
Jamie C Hey
NPI 1548271406
$10,203.30
in general payments reported to CMS, 2019-2025
38 companies · $2,456 in 2025
The $2,456 reported for 2025 was more than what 79% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $862 · 2020: $307 · 2021: $347 · 2022: $1,255 · 2023: $3,105 · 2024: $1,872 · 2025: $2,456.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,174 · Education: $258.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,174.44 |
| Education | $257.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $1,360.17 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Astrazeneca Pharmaceuticals LP | $1,118.29 | 2019-2025 | Airsupra, Tezspire, Fasenra |
| Actelion Pharmaceuticals US, INC. | $862.86 | 2019-2023 | Uptravi, Opsumit |
| Grifols USA, LLC | $851.12 | 2019-2025 | Prolastin-C Liquid, Xembify |
| Boehringer Ingelheim Pharmaceuticals, INC. | $767.52 | 2019-2025 | Ofev, Jascayd |
| Mallinckrodt Hospital Products INC. | $762.54 | 2020-2025 | Acthar |
| Regeneron Healthcare Solutions, INC. | $549.61 | 2019-2025 | Dupixent |
| Genzyme Corporation | $522.23 | 2022-2025 | |
| Genentech USA, INC. | $385.45 | 2019-2025 | Xolair |
| Insmed, INC. | $323.64 | 2019-2025 | Arikayce, Brinsupri |
| Amgen INC. | $290.66 | 2023-2025 | Tezspire |
| Vifor Pharma, INC. | $271.95 | 2024-2025 | Zemaira, Veltassa |
| Mylan Specialty L.P. | $260.87 | 2019-2024 | Yupelri |
| Ani Pharmaceuticals, INC. | $251.93 | 2023-2025 | Purified Cortrophin Gel |
| Takeda Pharmaceuticals U.S.A., INC. | $202.52 | 2024-2025 | Glassia, Cuvitru, Hyqvia |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Electromed, INC. | $155.02 | 2021-2025 | Smartvest |
| Paratek Pharmaceuticals, INC. | $147.20 | 2022-2024 | Nuzyra |
| Baxter Healthcare | $136.23 | 2024-2025 | Hillrom - Monarch Airway Clearance System |
| Merck Sharp & Dohme LLC | $120.36 | 2019-2024 | Winrevair |
| Pulmonx Corporation | $119.31 | 2023-2025 | Pulmonx Chartis Tablet Console, Zephyr Delivery Catheter, Zephyr Endobronchial Valve |
| Philips North America LLC | $114.54 | 2020-2024 | (Ak6) Vest Therapy |
| Inogen, INC. | $112.50 | 2022-2025 | Inogen One G5 Oxygen Concentrator - Bluetooth |
| Novartis Pharmaceuticals Corporation | $83.34 | 2022-2024 | |
| Pharming Healthcare, INC. | $65.53 | 2023-2024 | Ruconest |
| Gilead Sciences, INC. | $61.27 | 2019 | |
| United Therapeutics Corporation | $53.72 | 2022-2024 | Tyvaso |
| Intuitive Surgical, INC. | $44.23 | 2021 | |
| Sunovion Pharmaceuticals INC. | $37.11 | 2019 | |
| Atricure, INC. | $34.16 | 2025 | Atricure Cryoice Cryosphere Cryoablation System |
| 3b Medical, INC. | $23.45 | 2025 | Luna |
| Csl Behring | $21.36 | 2023 | Hizentra |
| Vapotherm INC | $19.37 | 2022 | |
| Nabriva Therapeutics, Plc | $17.98 | 2021 | |
| Janssen Pharmaceuticals, INC | $17.58 | 2021 | |
| Viatris Specialty LLC | $14.72 | 2025 | Yupelri |
| Bayer Healthcare Pharmaceuticals INC. | $12.00 | 2019 | |
| Advanced Respiratory, INC | $10.96 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jamie Hey listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.